Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Published:2017-12 Issue:12 Volume:2 Page:877-889
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Bazinet Michel,Pântea Victor,Cebotarescu Valentin,Cojuhari Lilia,Jimbei Pavlina,Albrecht Jeffrey,Schmid Peter,Le Gal Frédéric,Gordien Emmanuel,Krawczyk Adalbert,Mijočević Hrvoje,Karimzadeh Hadi,Roggendorf Michael,Vaillant Andrew

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference45 articles.

1. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead;Wedemeyer;Nat Rev Gastroenterol Hepatol,2010

2. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study;Stroffolini;J Med Virol,2009

3. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery;Noureddin;Curr Gastroenterol Rep,2014

4. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California;Gish;J Gastroenterol Hepatol,2013

5. Hepatitis D: thirty years after;Rizzetto;J Hepatol,2009

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virological markers for clinical trials in chronic viral hepatitis;JHEP Reports;2024-09

2. Nanopore efficiently identifies hepatitis D virus antigens in vitro assay;Materials Today Physics;2024-08

3. Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain;Viruses;2024-07-17

4. Hepatitis-D-Infektion: Prophylaxe und Therapie – Blick in die Zukunft;Deutsches Ärzteblatt Online;2024-04-19

5. Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future;Journal of Clinical Medicine;2024-04-02